Recent Company News

• 06:49 PM ET Jul 15, 2025
  

  Macquarie upgrades 1093.HK, 1801.HK; downgrades 9995.HK

• 09:59 AM ET Jul 07, 2025
  

  StreetAccount Sector Summary - China Healthcare June Recap

• 06:34 AM ET Jul 04, 2025
  

  NMPA issues drug registration approval to CSPC Pharma's mesalazine enteric-coated tablets to treat ulcerative colitis (HK$8.15, 0.00)

• 06:40 AM ET Jul 03, 2025
  

  NMPA approves CSPC Pharma's high-concentration hydroxocobalamin hydrochloride injection to clinical trial for treatment of methylmalonic acidemia (HK$8.24, 0.00)

• 08:07 PM ET Jun 22, 2025
  

  CSPC Pharmaceutical Group's Meloxicam Injection obtains drug registration approval from NMPA (HK$7.62, 0.00)

• 10:51 PM ET Jun 16, 2025
  

  StreetAccount Summary - Trading higher/lower: Hong Kong mid-morning

• 06:25 PM ET Jun 18, 2025
  

  UOB Kay Hian upgrades China biotech sector view to overweight from market weight; cites rapid innovation and sturdy product pipelines

• 08:51 AM ET Jun 13, 2025
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 04:44 AM ET Jun 13, 2025
  

  CSPC Pharmaceutical to collaborate with AstraZeneca on developing novel oral small molecule candidates using CSPC's AI-driven platform (HK$8.84, 0.00)